Abstract: The present invention aims to provide a lithium ion secondary cell configured to be charged by light such as solar light (particularly, UV light (for example, light having a wavelength of 350 nm to 400 nm)). The present invention relates to a lithium ion secondary cell including: a pair of substrates, at least one of the substrates being light transmitting; an electrolyte filled between the pair of substrates; a positive electrode that includes a positive electrode material selected from lithium-containing metal oxides and that is disposed to contact the electrolyte; and a negative electrode that includes a negative electrode material selected from n-type semiconductor materials and that is disposed to contact the electrolyte.

Abstract: The present invention is directed to creating a less-energy loss or smooth (constant) molten steel flow with a focus on a configuration of a bore of an upper nozzle, so as to provide an upper nozzle formed with a bore having a configuration capable of to suppress deposit formation. For this purpose, in an upper nozzle 10 for allowing molten steel to flow therethrough, a radius of an upper end of a bore 11 is set to be equal to or greater than 1.5 times a radius of a lower end of the bore 11, and a bore surface 14 is formed in a vertical cross-sectional configuration represented by log(r(z))=(1/n)×log((H+L)/(H+z))+log(r(L))(n=1.5 to 6).

Abstract: The present invention is directed to creating a less-energy loss or smooth (constant) molten steel flow with a focus on a configuration of a bore of an upper nozzle, so as to provide an upper nozzle formed with a bore having a configuration capable of to suppress deposit formation. For this purpose, in an upper nozzle 10 for allowing molten steel to flow therethrough, a radius of an upper end of a bore 11 is set to be equal to or greater than 1.5 times a radius of a lower end of the bore 11, and a bore surface 14 is formed in a vertical cross-sectional configuration represented by log(r (z))=(1/n)×log((H+L)/(H+z))+log(r (L))(n=1.5 to 6).

Abstract: In a disk unit for recording and reproducing information to and from a disk-like recording medium, a disk loading device includes a slot into which a disk-like recording medium is inserted; a retaining member that retains the disk-like recording medium inserted from the slot; a moving member that moves the retaining member so as to retract the disk-like recording medium in a disk insert direction during insertion and expel the disk-like recording medium in a disk eject direction during ejection; a drive mechanism that drives the moving member in the insert direction and the eject direction; and a manual drive member that, when pressed, slidingly engages the drive mechanism and drives the drive mechanism in the eject direction.

Abstract: A disk loading device includes a slot into which a disk-like recording medium is inserted, a retaining member that retains the disk-like recording medium inserted from the slot, a moving member that moves the retaining member so as to retract the disk-like recording medium in a disk insert direction during insertion and expel the disk-like recording medium in a disk eject direction during ejection, and a drive mechanism that, after the disk-like recording medium has moved to an eject position, drives the moving member from the eject position further in the eject direction so as to bring the retaining member adjacent to the slot as the disk-like recording medium is withdrawn from the slot.

Abstract: Optical parts are obtained from the thermoplastic resin compositions containing alicyclic polyester, e.g., polycyclohexanedimethanolcyclohexane dicarboxylate as the alicyclic resin. The thermoplastic resin compositions contain alicyclic polyester as well as polycarbonate with the polycarbonate: alicyclic polyester weight ratio is in the range of 0:100 to 95:5, for optical elements having excellent chemical resistance and transmittance characteristics.

Abstract: The carcinostatic agent of the present invention is an extract from seeds of Aeginetia indica and has interleukin-2 and interferon-.gamma. inducing potency. As shown in FIG. 1, all of the mice, to which this extract was not given, (.DELTA.) died from tumor (6 mice). In contrast, in the mice, to which the extract was given by 0.6 mg/kg (.quadrature.), 1.2 mg/kg (+), and 2.5 mg/kg ( ) intraperitoneally once in every two days from the day of tumor grafting, all mice showed increase in the survival rate. Thus, the extract exhibits excellent carcinostatic effect.

Abstract: A method for chemically modifying an anionic metal complex, by obtaining from an anionic metal complex insoluble in a non-aqueous solvent and a clathrate compound a clathrate complex thereof with a counter cation of said metal complex, which is soluble in a non-aqueous solvent, and then reacting functional groups of the metal complex, which are not concerned with the coordination of said metal complex, with an organic reagent in the presence of a reaction assistant.The central metal from the chemically modified metal complex may then be removed.

Abstract: A method for chemically modifying an anionic metal complex, by obtaining from an anionic metal complex, insoluble in a non-aqueous solvent and a clathrate compound a clathrate complex thereof with a counter cation of said metal complex, which is soluble in a non-aqueous solvent, and then reacting functional groups of the metal complex, which are not concerned with the coordination of said metal complex, with an organic reagent in the presence of a reaction assistant.

Abstract: A pharmaceutical composition for treating keratosic disorders of skin and mucosa, particularly, lichen planus and leukoplakia, by topical or local administration which comprises an effective amount of human interferon, a trihydric or more higher polyhydric sugar alcohol, an organic acid buffer and, optionally, an anionic surfactant and albumin, and a conventional pharmaceutical carrier or diluent. A method for treating a human subject suffering from keratosic disorders of skin and mucosa by using this composition is also provided.

Abstract: A pharmaceutical composition for treating erythematodes, particularly, lupus erythematodes discoides, or mycosis, particularly, candidasis, by topical or local administration which comprises an effective amount of human interferon, a trihydric or more higher polyhydric sugar alcohol, an organic acid buffer and, optionally, an anionic surfactant and albumin, and a conventional pharmaceutical carrier or diluent. A method for treating a human subject suffering from erythematodes and mycosis by using this composition is also provided.